After first-treatment approval, what is genuinely new is a regulated path: a one-time option that can teach cells to make a missing enzyme for eligible children in this disease lane.

New hope: a one-time option; cells can make the enzyme; skills may hold better than the old natural-history path in the studied window.

Still true: not every child yet; not an overnight cure; labs, steroids, travel to specialized centers, and years of follow-up still shape family life.

Wonder without overclaim. Both panels belong.